Track topics on Twitter Track topics that are important to you
Inotrem has reported positive results from a Phase IIa trial of nangibotide (LR12) for the treatment of septic shock patients....Read More... The post Inotrem reports positive data from Phase IIa tria...
The results were presented today at the annual congress of the International Sepsis Forum in Bangkok. Septic shock is the ultimate complication of sepsis and currently constitutes an The post Inotrem...
The study demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock Inotrem S.A., a biotechnology focused on the ...
Septic shock may no longer be as shocking in the future, as a Phase IIa trial brings hope for a personalized immunomodulatory treatment from the French biotech Inotrem. In sepsis, the immune system...
Inotrem is a biotechnology company specialized in the control of excessive immune response that occurs in acute inflammatory syndromes in the critical care setting. It has develop...
We have published hundreds of Inotrem S.A. news stories on BioPortfolio along with dozens of Inotrem S.A. Clinical Trials and PubMed Articles about Inotrem S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Inotrem S.A. Companies in our database. You can also find out about relevant Inotrem S.A. Drugs and Medications on this site too.